Carl L. Gordon, Director at Kinnate Biopharma Inc. (KNTE), bought 204,700 shares at $9.98 ($2.1M) on 2022-02-14, disclosed to the SEC on 2022-02-15.
Open-market purchase of $2.1M KNTE by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.22 | 156,000 | $1.6M | 76.7% |
| 2 | $9.89 | 10,000 | $99K | 4.8% |
| 3 | $9.98 | 20,700 | $207K | 9.9% |
| 4 | $9.96 | 9,000 | $90K | 4.3% |
| 5 | $9.96 | 9,000 | $90K | 4.3% |
| Total | $10.16 avg | 204,700 |
| $2.1M |
| 100% |
| Filing → |
| SCTX | BUY | 2026-07-29 | $15.0M | — | Filing → |
| CMPX | SELL | 2025-04-11 | $11.4M | — | Filing → |
| MBX | BUY | 2025-02-19 | $2.7M | — | Filing → |